Shanghai and Kunming work together to build a regional biomedical development ecosystem

For a long time, Shanghai and Kunming have carried out extensive and in-depth cooperation in transportation facilities interconnection, industrial cooperation docking, and scientific and technological synergy innovation, which has created a beautiful situation of integrated development of the Yangtze River Delta, reflecting the complementary advantages and coordinated development of regional cities. The vivid practice of mutual benefit and win-win.

The pharmaceutical industry is a dominant industry in the Yangtze River Delta region and plays a pivotal role in the national pharmaceutical industry. Over the years, Shanghai has promoted the development of the bio-pharmaceutical industry by strengthening industrial investment guidance and taking measures to promote the development of the bio-pharmaceutical industry. It has taken the lead in implementing the system of holders of drug and medical device marketing licenses, and established a bio-medicine industry fund with a scale of 50 billion, which has initially formed a gathering place for biomedicine and medical device industries such as Zhangjiang and Fengxian. The Kunshan bio-pharmaceutical industry, which has the advantage of “prospering Shanghai”, has also formed its own industrial characteristics while continuing to dock with Shanghai.

On the afternoon of November 28th, hosted by Kunshan Municipal People's Government, Kunshan Economic and Information Technology Commission and Kunshan Key Industry Development Promotion Center, Shanghai Biopharmaceutical Industry Association, Online Investment Fair, Shanghai Yumei Business Consulting Co., Ltd. The Kunshan Biomedical Industry Cooperation (Shanghai) Matchmaking Meeting co-organized by Shanghai Bianhong Intelligent Technology Co., Ltd. was held in Zhangjiang, Shanghai. The conference invited many top biomedical industry leaders, experts and scholars, leaders and investors from relevant departments of Shanghai and Kunming to discuss how to strengthen the cooperation between bio-pharmaceutical industry in Shanghai and Kunming, promote the transformation and application of technological innovation achievements, and cultivate world-class organisms. Topics such as the pharmaceutical industry cluster highlight the firm awareness of Kunshan City's active integration into the Yangtze River Delta's integrated development, and it also reflects the Kunshan municipal government's high regard for the biomedical industry.

Ten years of ploughing industry characteristics

It is no accident that Kunshan develops the bio-pharmaceutical industry. It is an important measure and strategic choice for the country to develop emerging industries. It is an important starting point for Kunshan's industrial transformation, upgrading and innovation.

Since the foundation of Kunshan Small Nucleic Acid Industry Base, the first small nucleic acid industry base in China, the Kunshan biomedical industry has achieved good results, including Ruibo Bio, Zeyi Pharmaceutical, Bochuang Tongkang, Suzhou Kunpeng, A number of outstanding enterprises such as Jikai Gene and Suzhou Huaxue have formed an industrial pattern with a small nucleic acid industry as the banner, new drug creation, medical equipment, biomaterials, and technical services, and a small nucleic acid public service in the Kunshan High-tech Zone. The platform, the National Torch Kunshan Small Nucleic Acid and Biomedical Industry Base and other three national-level innovation platforms, Jiangsu Province Small Nucleic Acid Application Innovation Center, Blood (Military Special Medicine) Base and other four provincial-level innovation platforms.

On the other hand, Kunshan also introduced 10 research laboratories such as Zhang Lihe, Academician Chen Xinzi, Professor Xi Zhen, Professor Liang Zicai and Professor Wang Jun; 2 academic institutes of Chen Runsheng and Professor Zhang Chenyu; There are 13 projects of 863 and nearly 50 science and technology projects of various provinces and above; more than 12 experts have introduced the “Thousand Talents Plan”.

It is reported that since 2018, Kunshan has introduced and newly started 35 bio-industry investment projects, with a registered capital of 683 million yuan and an additional investment of 3.36 billion yuan, including medical source medical technology and Bojing Biotechnology. The total investment of 7 projects including Kesen Medical Devices, New Yunda Biotechnology, Aikeer Medical Technology , Maples, and Hongqing Medical Inspection exceeded 100 million yuan. From January to October, the city's biomedical industry achieved sales of 5.76 billion yuan.

Talking about the development goals of Kunshan biomedical industry for three years, Jin Jianhong, the permanent deputy mayor of Kunshan Municipal Committee, said: "Our goal is to generate sales revenue of 30 billion yuan and cultivate a group of leading enterprises with core competitiveness and independent brands. 70 new drug research and development, 30 research and development of medical device products, 15 R&D institutions, 10 cooperation platforms with scientific research institutes, and a total of 70,000 square meters of new public incubation services, building a world-class small nucleic acid industry cluster. And an important domestic innovative bio-pharmaceutical industry base."

The escort policy service continues to increase

The report of the 19th National Congress pointed out that to implement the Healthy China Strategy, we must improve the national health policy and provide comprehensive and comprehensive health services for the people. The "Healthy China 2030" Planning Outline issued by the State Council aims to improve medical services, health protection and the health of the whole people, and promote the development of the health industry. The development of the biomedical industry is huge. The development of biomedicine and life health industry is of great significance to promote the optimization and upgrading of Kunshan's industrial structure, foster new development momentum, and achieve high quality development in the new era.

In order to cultivate a bigger and stronger industrial cluster, Kunshan established a leading group for the development of small nucleic acid and biomedical industry, and specially set up a key industrial development promotion center of Kunshan City, which strengthens the encouragement and guidance of the development of biomedical industry from the perspective of system and mechanism. Prepared the "Kunshan Biomedical and Life Health Industry Development Research Report", researched and formulated "Several Policies on Supporting the Development of Small Nucleic Acid and Biomedical Industry in the City (Trial)", and encouraged biomedical major projects and major teams to introduce and cultivate and industrial service platforms. Construction, industrial innovation and development, industrialization development, financial innovation, talent introduction and training, support the development of cross-border integration of industries, and expand the industrial chain. The awards and quotas are at a leading level compared with other cities in China.

As a core factor in the development of the biomedical industry, talent plays a vital role. In order to attract high-end industrial talents, Kunshan implemented the “Head Talents” project. The total amount of funding for the team project is up to 100 million yuan, and the individual project funding can reach up to 20 million yuan, providing financial security services for biomedical talent innovation.

The meeting also announced that the “Online Investment Fair” platform of the Biomedical Industry Cluster Innovation Center, which Kunshan is fully committed to, will be officially launched. It will pass two major systems (CRM Merchants Management System and Online Investment Conference 2.0 Smart of CIFIT) System), six major publicity channels (mainstream official website media reports, online news reports, new media topics, self-media platforms, international mainstream media short video distribution and "Golden Key Online Investment Fair" special issue brochure) docking online CIFIT authority The investment information release platform meets the needs of the capital parties, project parties and investment institutions to achieve accurate release and intelligent matching, and improve the docking efficiency of the project.

Regional cooperation to create the future of biomedical industry

The data shows that in 2016, the Yangtze River Delta region had 133 of the top 500 enterprises in the national pharmaceutical industry's main business income, accounting for 26.6% of the top 500 enterprises in the country; the main business income was 295.13 billion yuan, accounting for 27.7% of the top 500 enterprises in the country; the total profit reached 49.18 billion yuan, accounting for 25.9% of the top 500 enterprises in the country. The Yangtze River Delta region has a strong scale effect and competitive advantage in the pharmaceutical manufacturing industry.

However, the key enterprises in the pharmaceutical industry in the Yangtze River Delta region have lagged behind other major regions in China in recent years, and the industrial concentration is relatively weak. The reason is not only related to the slowdown in the development of key enterprises in the pharmaceutical industry in the Yangtze River Delta, but also to the lack of capacity of key enterprises in the pharmaceutical industry in the Yangtze River Delta.

According to Fu Dazhao, director of the Shanghai Pharmaceutical Science and Technology Industry Promotion Center and vice president of the Shanghai Biomedical Industry Association, Shanghai is formulating a three-year action plan for the coordinated development of the Yangtze River Delta industry, which will establish the development of the biomedical industry in the Yangtze River Delta region at the local government level. Coordination mechanism, establish a synergy platform for bio-pharmaceutical industry technology alliances across the Yangtze River Delta region, and foster and develop forms or forms of cooperative development based on industrial chains among pharmaceutical companies in the Yangtze River Delta.

"Industry synergy is the inevitable development of the Yangtze River Delta integration, and the development of comparative advantage and misplaced development is the prerequisite for mutual benefit and win-win. At present, Shanghai is making every effort to build a world-class manufacturing cluster, promoting regional linkage and industrial synergy innovation, Kunshan and Shanghai's related industries should focus on the development opportunities of the Yangtze River Delta integration and strive to create new advantages in the competition of the bio-pharmaceutical industry. The bio-pharmaceutical industry in Shanghai and Kunming has the potential and conditions to work together for common development." Shanghai Economic and Shi Wenjun, deputy inspector of the Information Technology Committee and director of the Shanghai Economic and Information Development Research Center, said.

"We firmly believe that cross-regional industrial cooperation can promote the bio-pharmaceutical industry to carry out better application-oriented development and inject momentum into the high-quality integrated development of the Yangtze River Delta. We will take this event as an opportunity to build a bridge of friendship and build a win-win situation. The bond, the power of innovation, and the future of sharing,” said Zhang Yuelin, deputy secretary of the Kunshan Municipal Committee of the Communist Party of China.

X Ray Short Lead Apron

X Ray Short Lead Apron,0.35Mmpb Short Lead Apron X-Ray,0.5Mmpb Xray Short Lead Apron,Xray Protection Short Apron

Longkou Kangxie Medical Instrument Co., Ltd , https://www.lkmradiology.com